Trial Profile
WAVE: Weekly nab-paclitaxel (Abraxane) Versus Epirubicin in women with early breast cancer who are elderly or unfit for a 3-weekly polychemotherapy regimen: a Phase II Randomized Trial evaluating Activity and Quality of Life.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Epirubicin
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms WAVE
- 26 Feb 2018 New trial record